---
title: "3SBio H1 FY26 net profit rises 26.5% to RMB 1.44 billion; revenue increases 3.9% to RMB 4.53 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296580744.md"
description: "3SBio reported H1 FY26 adjusted operating net profit of RMB 1.44 billion, a 26.5% increase, with revenue rising 3.9% to RMB 4.53 billion. Overseas sales surged 43%, driven by rhEPO and other products in emerging markets. R&D expenses grew 24.9% to RMB 680 million as the company focuses on oncology, autoimmune diseases, and nephrology."
datetime: "2026-08-21T07:25:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296580744.md)
  - [en](https://longbridge.com/en/news/296580744.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296580744.md)
generator: "portal-rs"
---

# 3SBio H1 FY26 net profit rises 26.5% to RMB 1.44 billion; revenue increases 3.9% to RMB 4.53 billion

-   3SBio posted first-half 2026 revenue of RMB 4.53 billion, up 3.9% year over year. \* Net profit attributable to equity holders rose to RMB 1.15 billion; adjusted operating net profit attributable to shareholders climbed 26.5% to RMB 1.44 billion. \* R&D expenses increased 24.9% to RMB 680 million; financial resources totaled RMB 19.4 billion. \* Overseas product sales rose 43% year over year as rhEPO, Yisaipu and rhTPO gained traction in emerging markets. \* Chairman and CEO Jing LOU said 3SBio will keep lifting R&D investment, focusing on oncology, autoimmune diseases and nephrology. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 3SBio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608210324PR\_NEWS\_USPR\_\_\_\_\_CN31191) on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01530.HK](https://longbridge.com/en/quote/01530.HK.md)
- [688336.CN](https://longbridge.com/en/quote/688336.CN.md)

## Related News & Research

- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [China Traditional Chinese Medicine Holdings schedules board meeting to review interim results](https://longbridge.com/en/news/296200801.md)
- [11:25 ETILD Day 2026 Spotlights Precision Medicine's Potential to Transform Patient Care](https://longbridge.com/en/news/296512797.md)
- [CMI adopts orphan drug field with dedicated center of excellence](https://longbridge.com/en/news/296242891.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**